Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts

Key Points

• Neumora Therapeutics, Inc. has received an average recommendation of "Hold" from analysts, with one sell rating, five holds, and three buy ratings.
• The company's average 12-month price target among analysts is $7.14, despite the stock currently trading around $1.66.
• Neumora is engaged in developing therapies for neurodegenerative diseases and has a promising candidate, navacaprant, currently in phase 3 clinical trials for major depressive disorder.

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have been assigned an average recommendation of "Hold" from the nine brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $7.1429.

NMRA has been the topic of a number of analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $5.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, May 13th. Mizuho lifted their target price on Neumora Therapeutics from $4.00 to $5.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th.

Neumora Therapeutics Trading Down 1.2%

Shares of NMRA opened at $1.66 on Tuesday. The business's 50-day moving average price is $1.58 and its 200 day moving average price is $1.15. The stock has a market capitalization of $268.84 million, a P/E ratio of -1.06 and a beta of 2.92. Neumora Therapeutics has a 1-year low of $0.61 and a 1-year high of $17.19. The company has a current ratio of 10.54, a quick ratio of 10.54 and a debt-to-equity ratio of 0.11.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.05. Analysts expect that Neumora Therapeutics will post -1.61 earnings per share for the current year.

Hedge Funds Weigh In On Neumora Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Rafferty Asset Management LLC purchased a new position in Neumora Therapeutics during the 4th quarter valued at about $185,000. BNP Paribas Financial Markets purchased a new position in Neumora Therapeutics during the 4th quarter valued at about $221,000. Jump Financial LLC purchased a new position in Neumora Therapeutics during the 1st quarter valued at about $25,000. CWM LLC lifted its holdings in shares of Neumora Therapeutics by 7,124.4% during the 1st quarter. CWM LLC now owns 25,213 shares of the company's stock valued at $25,000 after buying an additional 24,864 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in shares of Neumora Therapeutics during the 4th quarter valued at about $281,000. Hedge funds and other institutional investors own 47.65% of the company's stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.